Who is sponsoring NCT03485885?

NCT03485885 is sponsored by Anklam Extrakt.

What drugs are being tested in NCT03485885?

Interventions in NCT03485885: Standardized maqui berry extract enriched in anthocyanins.

What condition does NCT03485885 study?

NCT03485885 studies Bioavailability.

Is NCT03485885 still recruiting?

NCT03485885 is currently completed. Last updated 10 January 2019.

Last reviewed 2019-01-10 · How we verify

NCT03485885

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects

Completed Last updated 10 January 2019

What this trial tests

trial testing Standardized maqui berry extract enriched in anthocyanins in Bioavailability in 12 participants. Completed in 12 December 2017.

Timeline

23 November 2017

Primary endpoint
12 December 2017

12 December 2017

Quick facts

Lead sponsor	Anklam Extrakt
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12
Start date	23 November 2017
Primary completion	12 December 2017
Estimated completion	12 December 2017
Sites	1 location across Germany

Drugs / interventions tested

Standardized maqui berry extract enriched in anthocyanins

Conditions studied

Bioavailability — all drugs for Bioavailability →

Sponsor

Anklam Extrakt

Who can join

Adults 18 to 50, any sex, with Bioavailability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present study is to describe the bioavailability for the proprietary standardized maqui berry extracts Delphinol® and MaquiBright® enriched in anthocyanins and in particular delphinidins. The analyses are based on two selected key substances namely delphinidin-3-glucoside and cyanidin-3-sambubioside and their metabolism to phenolic acids. The bioavailability of anthocyanins specific for Delphinol®/MaquiBright® was analyzed in plasma sample kinetics (at 0h, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h and 8h after intake of 1000mg standardized maqui berry extract in capsules) in 12 healthy subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Bioavailability Study of Maqui Berry Extract in Healthy Subjects.
Schön C, Wacker R, Micka A, Steudle J, et al · · 2018 · cited 27× · PMID 30423989 · DOI 10.3390/nu10111720

Verify or expand the search:

Other recruiting trials for Bioavailability

Currently open trials in the same condition.

NCT07063173 — Bioavailability of Ration Items Containing Tart Cherry Extract · NA · recruiting
NCT05774704 — Curcumin and Retinal Study · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03485885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anklam Extrakt
Last refreshed: 10 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03485885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing